Results 171 to 180 of about 70,385 (287)

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it? [PDF]

Reumatologia, 2021
Kucharz EJ, Kotulska-Kucharz A.
europepmc   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2212-2219, July 2026.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source

Mosaic STAT5B gain-of-function associated with demyelinating disease and autoimmunity. [PDF]

J Hum Immun
Schmitt EG, Saucier N, Risma SI, Arbag SN, Kolicheski A, Paul AJ, Toler TL, Semkiu K, Mar SS, Milner JD, Bednarski JJ, Cooper MA.   +11 more
europepmc   +1 more source

Biological aging of CNS-resident cells alters the clinical course and immunopathology of autoimmune demyelinating disease. [PDF]

JCI Insight, 2022
Atkinson JR, Jerome AD, Sas AR, Munie A, Wang C, Ma A, Arnold WD, Segal BM.   +7 more
europepmc   +1 more source

A Case of Longitudinal Extensive Transversal Myelitis in Patient With Neuromyelitis Optica Spectrum Disorder and Systemic Lupus Erythematosus

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune, demyelinating disorder of the central nervous system. Clinical manifestations include optic neuritis, longitudinally extensive transverse myelitis (LETM) involving three or more vertebral segments, and, in most cases, seropositivity for anti‐aquaporin‐4 antibodies (AQP4‐IgG).
Nikolina Pravdic, Marijana Goluza, Natasa Pejanovic Skobic, Davor Batinic, Jelena Zovko, Tanja Zovko, Anita Ivankovic, Inge Klupka Saric   +7 more
wiley   +1 more source

Copper Deficiency-Induced Neuropathy After Bariatric Surgery Disguised as Demyelinating Disease: A Case Report. [PDF]

Cureus, 2022
Amin A, Khoury NC, Lacayo M, Kostanyan S.   +3 more
europepmc   +1 more source

Can Multiple Sclerosis be Managed Over a Lifetime? A Rare 72‐Year Journey of Pediatric‐Onset to Secondary Progressive Multiple Sclerosis

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system characterized by cumulative neurological disability over time. Median survival from symptom onset in large cohort studies is approximately four decades, although substantially prolonged disease courses are uncommon.
Masoud Etemadifar, Ahmadreza Dehghani, Mahdi Rahimi, Amirhossein Ghandehari, Mehri Salari   +4 more
wiley   +1 more source

Blurred by a "Puff of Smoke"-A Case-Based Review on the Challenging Recognition of Coexisting CNS Demyelinating Disease and Moyamoya Angiopathy. [PDF]

Int J Mol Sci
Canavero I, Rifino N, Antozzi C, Caldiera V, Colombo E, Carrozzini T, Ganci G, Ferroli P, Acerbi F, Storti B, Boncoraglio GB, Potenza A, Pollaci G, Gorla G, Ciceri E, De Marco P, Gatti L, Bersano A.   +17 more
europepmc   +1 more source

A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2021
Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA.   +19 more
europepmc   +1 more source

Sustained Treatment Success With Ustekinumab in Symptomatic Stricturing Crohn's Disease: A Retrospective Single‐Arm Observational Cohort Study

MedComm, Volume 7, Issue 7, July 2026.
Data on ustekinumab (UST) for symptomatic stricturing Crohn's disease remain scarce in China. This cohort study screened 73 patients from June 2022 to April 2024, of whom 54 were eligible included, with 81.5% achieving 52‐week treatment success. Most attained sustained clinical remission alongside improved inflammation and strictures. Nonsmoking status
Jingwen Liu, Wen Hu, Shuyan Li, Shurong Hu, Deming Jiang, Yan Chen   +5 more
wiley   +1 more source